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Neuroblastoma is a pediatric cancer of neural crest origin
that accounts for 12% of all pediatric cancer deaths.
Despite improved survival in patients that receive stan-
dard care plus anti-GD2 immune therapy, there remains
a 40% mortality rate in high-risk patients. This high mor-
tality emphasizes the need for continued testing of
immune-based therapies for the treatment of refractory
neuroblastoma. Using a murine model, we previously
observed a cell-mediated immune response resulting in
elimination of established neuroblastoma when mice
were given a whole-cell tumor vaccine expressing CD80,
CD86, CD54 and CD137L. Given the anti-tumor efficacy
of this immune-based therapy, we designed and tested a
more clinically translatable protocol for the treatment of
established neuroblastoma. In this study, unmodified
tumor cell lysate and the TLR9 ligand, CpG-ODN 1826
(CpG), was given as immune therapy in combination
with cyclophosphamide (CY). To establish tumor burden,
mice were inoculated subcutaneously (s.c.) with 10E5 live
neuroblastoma cells. Four and five days following tumor
inoculation mice received 100 mg/kg intravenous cyclo-
phosphamide. Nine 16, 23, and 30 days following tumor
inoculation some mice received the tumor cell lysate and
CpG immune therapy. When only CY was administered,
all mice succumbed to tumor. When tumor lysate and
CpG were added to the CY treatment protocol, tumors
regressed and there was 60% survival. Immune cell analy-
sis revealed an increase in activated mature (I-Ak+CD11c
+) dendritic cells in the spleen and draining lymph nodes
of mice that received CY, CpG and tumor lysate. We also
found evidence of an adaptive immune response. Mice
treated with CY, CpG and tumor lysate had an increase
in the percentage of Ki67+ proliferating splenic CD4 and
CD8 T cells. In addition, there was an increase in T effec-
tor memory (CD44hiCD62Llo) cells in the spleens of
mice treated with Cy, lysate and CpG. Splenic T cells
harvested from these mice produced interferon gamma
(IFN-g) when exposed to neuroblastoma tumor cells. Of
great importance for clinical translation, when either
autologous or allogeneic lysate was given in combination
with CY and CpG, IFN-g was produced in tumor-specific
splenic CD8 T cells. Survival curves were similar regard-
less of administration of autologous or allogeneic tumor
lysate. We are continuing to explore the treatment-
related immune mechanisms that promote tumor regres-
sion with hope for clinical translation of this protocol.
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